Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nitrendipine kinetics in normal and impaired renal function.

G R Aronoff, R S Sloan

    Clinical Pharmacology and Therapeutics
    |August 1, 1985
    PubMed
    Summary

    Renal insufficiency does not affect nitrendipine (a calcium channel blocker) absorption or metabolism. This study found no significant changes in nitrendipine kinetics in patients with impaired kidney function.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Goal setting & Network 9/10 efforts to improve care.

    Nephrology news & issues·2002
    Same author

    NephTrak and the Renal Network Data System (TRNDS).

    Nephrology news & issues·2002
    Same author

    Hearing the silence of patients who did not receive an anticipated organ transplant: "being second in line".

    ANNA journal·2000
    Same author

    Guarded alliance relationships between hemodialysis patients and their health care providers.

    ANNA journal·2000
    Same author

    Tyrosine phosphorylation of human platelet plasma membrane Ca(2+)-ATPase in hypertension.

    Hypertension (Dallas, Tex. : 1979)·2000
    Same author

    Treatment of cryptococcal arthritis with fluconazole monotherapy.

    The Journal of the Kentucky Medical Association·1998

    Area of Science:

    • Pharmacology
    • Nephrology
    • Clinical Therapeutics

    Background:

    • Nitrendipine is a widely used calcium channel blocker for hypertension.
    • The impact of renal failure on nitrendipine pharmacokinetics and pharmacodynamics is not fully understood.
    • Understanding drug metabolism and elimination in renal dysfunction is crucial for patient safety.

    Purpose of the Study:

    • To investigate the effect of renal failure on the absorption, metabolism, and excretion of nitrendipine and its metabolites.
    • To determine if impaired renal function alters nitrendipine's pharmacokinetic parameters.
    • To assess the relationship between nitrendipine plasma concentrations and blood pressure response in patients with varying degrees of renal function.

    Main Methods:

    • A single oral dose of 20 mg nitrendipine was administered to 6 healthy men and 16 men with renal dysfunction.
    • Plasma concentrations of nitrendipine and its pyridine analog metabolite were measured using High-Performance Liquid Chromatography (HPLC) over 48 hours.
    • Urinary excretion of four additional metabolites was quantified.
    • Arterial blood pressure was monitored throughout the study period.

    Main Results:

    • The mean elimination half-life (t1/2) for nitrendipine was 2.8 ± 2.1 hours, and for its metabolite was 3.4 ± 3.9 hours.
    • No significant alterations in pharmacokinetic parameters were observed in patients with decreased renal function.
    • Plasma nitrendipine concentrations correlated with a decrease in blood pressure, but metabolite concentrations did not show this correlation.

    Conclusions:

    • Renal insufficiency does not significantly alter the absorption, metabolism, or elimination kinetics of nitrendipine in humans.
    • Nitrendipine's antihypertensive effect appears to be maintained in patients with renal impairment.
    • The study suggests that dose adjustments for nitrendipine may not be necessary in patients with renal dysfunction based on altered drug kinetics.

    Related Experiment Videos